PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
10532632-1	1999	The novel mGluR agonist LY354740 and a related analogue LY379268 are selective for mGluR2/3 receptors and are centrally active after systemic administration.	LY 379268	56-64	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	83-89
10515191-2	1999	Loss of CA1 hippocampal neurones following 5 min bilateral occlusion of the carotid artery (BCAO) in the gerbil was almost completely prevented by LY379268 (10 mg/kg, i.p.)	LY 379268	147-155	carbonic anhydrase 1	Rattus norvegicus	8-11
10532632-9	1999	These results show the important functional involvement of the limbic system together with the participation of components of different sensory systems in response to the activation of mGluR2 and mGluR3 with LY354740 and LY379268.	LY 379268	221-229	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	185-191
10532632-9	1999	These results show the important functional involvement of the limbic system together with the participation of components of different sensory systems in response to the activation of mGluR2 and mGluR3 with LY354740 and LY379268.	LY 379268	221-229	glutamate receptor, ionotropic, AMPA3 (alpha 3)	Mus musculus	196-202
35230468-11	2022	LY379268 (1 mg/kg) attenuated CS + evoked increases in both water-associated lever pressing and conditioned approach to the water port.	LY 379268	0-8	citrate synthase	Rattus norvegicus	30-32
33763176-4	2021	The application of agonists of mGluR3 (N-acetylaspartylglutamate; NAAG) or mGluR2 (LY379268) inhibits the release of glutamate and reduces neurodegeneration in a neonatal rat model of HI, although the exact mechanism is not fully recognized.	LY 379268	83-91	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	75-81
33763176-9	2021	Application of NAAG or LY379268 24 h or 1 h before HI reduced HIF-1alpha formation likely by reducing ROS levels.	LY 379268	23-31	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	62-72
33763176-10	2021	It was shown that LY379268 concentration remains at a level that is required for activation of mGluR2 for up to 24 h; however, NAAG is quickly metabolized by glutamate carboxypeptidase II (GCPII) into glutamate and N-acetyl-aspartate.	LY 379268	18-26	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	95-101
33763176-10	2021	It was shown that LY379268 concentration remains at a level that is required for activation of mGluR2 for up to 24 h; however, NAAG is quickly metabolized by glutamate carboxypeptidase II (GCPII) into glutamate and N-acetyl-aspartate.	LY 379268	18-26	folate hydrolase 1	Rattus norvegicus	189-194
33763176-11	2021	The observed effect of LY379268 application 24 h or 1 h before HI is connected with direct activation of mGluR2 and inhibition of glutamate release.	LY 379268	23-31	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	105-111
29793154-2	2018	The mGluR2/3 agonist LY379268 (LY37) attenuates excitatory N-methyl-D-aspartate receptor (NMDAR)-induced neurotoxicity, a central pathological characteristic of glutamatergic hypofunction.	LY 379268	21-25	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	4-10
29793154-2	2018	The mGluR2/3 agonist LY379268 (LY37) attenuates excitatory N-methyl-D-aspartate receptor (NMDAR)-induced neurotoxicity, a central pathological characteristic of glutamatergic hypofunction.	LY 379268	21-29	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	4-10
34416343-0	2021	Rescue of BDNF Expression by the Thalamic Parafascicular Nucleus with Chronic Treatment with the mGluR2/3 Agonist LY379268 may Contribute to the LY379268 Rescue of Enkephalinergic Striatal Projection Neurons in R6/2 Huntington"s Disease Mice.	LY 379268	114-122	brain derived neurotrophic factor	Mus musculus	10-14
34416343-0	2021	Rescue of BDNF Expression by the Thalamic Parafascicular Nucleus with Chronic Treatment with the mGluR2/3 Agonist LY379268 may Contribute to the LY379268 Rescue of Enkephalinergic Striatal Projection Neurons in R6/2 Huntington"s Disease Mice.	LY 379268	114-122	glutamate receptor, metabotropic 2	Mus musculus	97-105
34416343-0	2021	Rescue of BDNF Expression by the Thalamic Parafascicular Nucleus with Chronic Treatment with the mGluR2/3 Agonist LY379268 may Contribute to the LY379268 Rescue of Enkephalinergic Striatal Projection Neurons in R6/2 Huntington"s Disease Mice.	LY 379268	145-153	brain derived neurotrophic factor	Mus musculus	10-14
34416343-0	2021	Rescue of BDNF Expression by the Thalamic Parafascicular Nucleus with Chronic Treatment with the mGluR2/3 Agonist LY379268 may Contribute to the LY379268 Rescue of Enkephalinergic Striatal Projection Neurons in R6/2 Huntington"s Disease Mice.	LY 379268	145-153	glutamate receptor, metabotropic 2	Mus musculus	97-105
34416343-1	2021	We have found that daily subcutaneous injection with a maximum tolerated dose of the mGluR2/3 agonist LY379268 (20 mg/kg) beginning at 4 weeks of age dramatically improves the motor, neuronal and neurochemical phenotype in R6/2 mice, a rapidly progressing transgenic model of Huntington"s disease (HD).	LY 379268	102-110	glutamate receptor, metabotropic 2	Mus musculus	85-93
34416343-2	2021	We also previously showed that the benefit of daily LY379268 in R6/2 mice was associated with increases in corticostriatal brain-derived neurotrophic factor (BDNF), and in particular was associated with a reduction in enkephalinergic striatal projection neuron loss.	LY 379268	52-60	brain derived neurotrophic factor	Mus musculus	123-156
34416343-2	2021	We also previously showed that the benefit of daily LY379268 in R6/2 mice was associated with increases in corticostriatal brain-derived neurotrophic factor (BDNF), and in particular was associated with a reduction in enkephalinergic striatal projection neuron loss.	LY 379268	52-60	brain derived neurotrophic factor	Mus musculus	158-162
34416343-3	2021	In the present study, we show that daily LY379268 also rescues expression of BDNF by neurons of the thalamic parafascicular nucleus in R6/2 mice, which projects prominently to the striatum, and this increase too is linked to the rescue of enkephalinergic striatal neurons.	LY 379268	41-49	brain derived neurotrophic factor	Mus musculus	77-81
34416343-4	2021	Thus, LY379268 may protect enkephalinergic striatal projection neurons from loss by boosting BDNF production and delivery via both the corticostriatal and thalamostriatal projection systems.	LY 379268	6-14	brain derived neurotrophic factor	Mus musculus	93-97
34330748-5	2021	Treatment of both male and female zQ175 mice with the potent and selective mGluR2/3 agonist LY379268 for either 4 or 8 weeks improves both limb coordination and locomotor function in all mice.	LY 379268	92-100	glutamate receptor, metabotropic 2	Mus musculus	75-83
34330748-6	2021	LY379268 also reduces mutant huntingtin aggregate formation, neuronal cell death, and microglia activation in the striatum of both male and female zQ175 mice.	LY 379268	0-8	huntingtin	Mus musculus	29-39
34330748-8	2021	Furthermore, LY379268 reduces both Akt and ERK1/2 phosphorylation in male zQ175 mice but increases both Akt and ERK1/2 phosphorylation in female zQ175 mice.	LY 379268	13-21	thymoma viral proto-oncogene 1	Mus musculus	35-38
34330748-8	2021	Furthermore, LY379268 reduces both Akt and ERK1/2 phosphorylation in male zQ175 mice but increases both Akt and ERK1/2 phosphorylation in female zQ175 mice.	LY 379268	13-21	mitogen-activated protein kinase 3	Mus musculus	43-49
34330748-8	2021	Furthermore, LY379268 reduces both Akt and ERK1/2 phosphorylation in male zQ175 mice but increases both Akt and ERK1/2 phosphorylation in female zQ175 mice.	LY 379268	13-21	thymoma viral proto-oncogene 1	Mus musculus	104-107
34330748-8	2021	Furthermore, LY379268 reduces both Akt and ERK1/2 phosphorylation in male zQ175 mice but increases both Akt and ERK1/2 phosphorylation in female zQ175 mice.	LY 379268	13-21	mitogen-activated protein kinase 3	Mus musculus	112-118
34330748-11	2021	Significance Statement The mGluR2/3 agonist LY379268 improves motor impairments and reduces pathology in male and female zQ175 Huntington"s mice.	LY 379268	44-52	glutamate receptor, metabotropic 2	Mus musculus	27-35
35248529-7	2022	In Mecp2Null/+ mice, treatment with the mGlu2/3 agonist LY379268 reverses the deficit in trace fear acquisition, and mGlu2/3 antagonism with LY341495 normalizes the abnormal trace fear learning and memory phenotype in MECP2Tg1/o mice.	LY 379268	56-64	methyl CpG binding protein 2	Mus musculus	3-8
35248529-7	2022	In Mecp2Null/+ mice, treatment with the mGlu2/3 agonist LY379268 reverses the deficit in trace fear acquisition, and mGlu2/3 antagonism with LY341495 normalizes the abnormal trace fear learning and memory phenotype in MECP2Tg1/o mice.	LY 379268	56-64	glutamate receptor, metabotropic 3	Mus musculus	40-47
35091538-4	2022	We found that an obesogenic diet reduced goal-directed control and that systemic injection of LY379268, a Group II metabotropic glutamate receptor (mGluR2/3) agonist, returned goal-directed responding in these rats.	LY 379268	94-102	glutamate receptor, metabotropic 2	Mus musculus	148-156
32534177-7	2021	The current study evaluated the effect of mGluR2/3 agonist LY379268 (LY37) in BLA on stress and fear memory induced changes in sleep, EEG spectra, behavioral fear expression and physiological stress.	LY 379268	59-67	glutamate receptor, metabotropic 2	Mus musculus	42-50
34010316-5	2021	Compared with that in the sham control group, chronic LY379268 application (mGluR2/3 agonist; 0.40 mug/day) to the dorsal medulla oblongata for 6 weeks reduced the progression of hypertension in 6-week-old SHRs as indicated by the 40 mmHg reduction in systolic blood pressure and promoted their parasympathetic nervous activity as evidenced by the heart rate variability.	LY 379268	54-62	glutamate receptor, metabotropic 2	Mus musculus	76-84
32534177-7	2021	The current study evaluated the effect of mGluR2/3 agonist LY379268 (LY37) in BLA on stress and fear memory induced changes in sleep, EEG spectra, behavioral fear expression and physiological stress.	LY 379268	59-63	glutamate receptor, metabotropic 2	Mus musculus	42-50
32765286-4	2020	The mGlu2/3 agonist LY379268 (1000 pM) significantly inhibited the 15 mM KCl-evoked [3H]D-Asp overflow from control synaptosomes, but not in terminals isolated from injured animals.	LY 379268	20-28	glutamate receptor, metabotropic 3	Mus musculus	4-11
32858088-6	2020	Treatment of 9w astrocytes with LY379268 resulted in an increase in mGlu3R and Nrf2 protein levels and SOD activity, and decreased mitochondrial ROS levels and apoptosis.	LY 379268	32-40	NFE2 like bZIP transcription factor 2	Rattus norvegicus	79-83
31536785-5	2019	Since we show that both sAPPalpha and the mGlu3R agonist LY379268 increased expression of class-A scavenger receptor (SR-A) in astrocytes, we next determined whether SR-A mediates mGlu3R- or sAPPalpha-induced Abeta uptake by using astrocyte cultures derived from SR-A knockout mice.	LY 379268	57-65	macrophage scavenger receptor 1	Mus musculus	118-122
31580222-0	2019	The mGluR2/3 agonist LY379268 reverses NMDA receptor antagonist effects on cortical gamma oscillations and phase coherence, but not working memory impairments, in mice.	LY 379268	21-29	glutamate receptor, metabotropic 2	Mus musculus	4-12
31580222-3	2019	AIMS: We studied relationships between cognitive impairment and gamma abnormalities following NMDAr antagonism, and attempted to reverse deficits with the metabotropic glutamate receptor type 2/3 (mGluR2/3) agonist LY379268.	LY 379268	215-223	glutamate receptor, metabotropic 2	Mus musculus	197-205
31536785-6	2019	We found that the effects of LY379268 as well as sAPPalpha on Abeta uptake were abolished in SR-A-deficient astrocytes, indicating a major role for this scavenger receptor in LY379268- and sAPPalpha-stimulated Abeta clearance by astrocytes.	LY 379268	29-37	macrophage scavenger receptor 1	Mus musculus	93-97
31536785-6	2019	We found that the effects of LY379268 as well as sAPPalpha on Abeta uptake were abolished in SR-A-deficient astrocytes, indicating a major role for this scavenger receptor in LY379268- and sAPPalpha-stimulated Abeta clearance by astrocytes.	LY 379268	175-183	macrophage scavenger receptor 1	Mus musculus	93-97
29499271-1	2018	Presynaptic mGlu2/3 autoreceptors exist in rat spinal cord nerve terminals as suggested by the finding that LY379268 inhibited the 15 mM KCl-evoked release of [3H]D-aspartate ([3H]D-Asp) in a LY341495-sensitive manner.	LY 379268	108-116	glutamate receptor, metabotropic 3	Mus musculus	12-19
29858599-4	2019	Among the five mGlu2 receptor-phosphorylated residues identified in HEK-293 cells, the phosphorylation of Ser843 was enhanced upon mGlu2 receptor stimulation by the orthosteric agonist LY379268 only in cells co-expressing the 5-HT2A receptor.	LY 379268	185-193	5-hydroxytryptamine receptor 2A	Homo sapiens	226-241
30867285-5	2019	Both ketamine and (2R,6R)-HNK prevented mGlu2/3 receptor agonist (LY379268)-induced body temperature increases in mice lacking the Grm3, but not Grm2, gene.	LY 379268	66-74	glutamate receptor, metabotropic 3	Mus musculus	131-135
30448990-3	2019	In this study, we investigated whether chronic treatment with the mGlu2/3 agonist LY379268 would alter the behavioral response to a phenethylamine hallucinogen, 25CN-NBOH, which acts as a selective 5-HT2A agonist.	LY 379268	82-90	glutamate receptor, metabotropic 3	Mus musculus	66-73
30448990-3	2019	In this study, we investigated whether chronic treatment with the mGlu2/3 agonist LY379268 would alter the behavioral response to a phenethylamine hallucinogen, 25CN-NBOH, which acts as a selective 5-HT2A agonist.	LY 379268	82-90	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	198-204
31208524-7	2019	LY379268, a selective metabolomic glutamate receptor 2/3 (mGluR2/3) receptor agonist, also upregulates the SIRT1/PGC-1alpha/TFAM signaling pathway and prevents DPN through glutamate recycling in Schwann/satellite glial (SG) cells and by improving dorsal root ganglion (DRG) neuronal Mt function.	LY 379268	0-8	sirtuin 1	Homo sapiens	107-112
31208524-7	2019	LY379268, a selective metabolomic glutamate receptor 2/3 (mGluR2/3) receptor agonist, also upregulates the SIRT1/PGC-1alpha/TFAM signaling pathway and prevents DPN through glutamate recycling in Schwann/satellite glial (SG) cells and by improving dorsal root ganglion (DRG) neuronal Mt function.	LY 379268	0-8	PPARG coactivator 1 alpha	Homo sapiens	113-123
31208524-7	2019	LY379268, a selective metabolomic glutamate receptor 2/3 (mGluR2/3) receptor agonist, also upregulates the SIRT1/PGC-1alpha/TFAM signaling pathway and prevents DPN through glutamate recycling in Schwann/satellite glial (SG) cells and by improving dorsal root ganglion (DRG) neuronal Mt function.	LY 379268	0-8	transcription factor A, mitochondrial	Homo sapiens	124-128
30564095-6	2018	Treatment with the selective mGlu2/3 receptors agonist LY379268 also increased the amount of Gadd45-beta bound to specific promoter regions of reelin, BDNF, and GAD67.	LY 379268	55-63	growth arrest and DNA-damage-inducible 45 beta	Mus musculus	93-104
30564095-6	2018	Treatment with the selective mGlu2/3 receptors agonist LY379268 also increased the amount of Gadd45-beta bound to specific promoter regions of reelin, BDNF, and GAD67.	LY 379268	55-63	brain derived neurotrophic factor	Mus musculus	151-155
30301879-5	2018	Conducting a comprehensive phenotyping of CD2-KO mice, we found that they displayed novelty-induced hyperlocomotion (a rodent correlate of positive symptoms of schizophrenia), that was largely resistant against D1- and D2-dopamine-receptor antagonism, but responsive to the mGluR2/3-agonist LY379268.	LY 379268	291-299	CD2 antigen	Mus musculus	42-45
30301879-8	2018	However, in the cognitive domain, CD2-knockouts showed reduced executive function in assays of rule-shift and rule-reversal learning, and also an impairment in working memory, that was resistant against LY379268-treatment.	LY 379268	203-211	CD2 antigen	Mus musculus	34-37
30005976-6	2018	In control Wistar but not in Han Wistar rats the mGluR2/3 agonist LY379268 (3 & 10 mg/kg) induced REM sleep suppression with dose-dependent effects on wake and NREM sleep.	LY 379268	66-74	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	49-55
29524437-5	2018	We showed that the orthosteric mGluR2 agonist LY379268 (0.1 microM, 1 microM and 10 microM) and mGluR5 positive allosteric modulator CDPPB (1 microM and 10 microM) both attenuated potassium-evoked dopamine release, underscoring their role in modulating dopamine neurotransmission in the nucleus accumbens.	LY 379268	46-54	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	31-37
29858599-7	2019	In both HEK-293 cells and prefrontal cortex, Ser843 phosphorylation elicited by 5-HT2A receptor stimulation was prevented by the mGlu2 receptor antagonist LY341495, while the LY379268-induced effect was abolished by the 5-HT2A receptor antagonist M100907.	LY 379268	175-183	5-hydroxytryptamine receptor 2A	Homo sapiens	80-95
29858599-7	2019	In both HEK-293 cells and prefrontal cortex, Ser843 phosphorylation elicited by 5-HT2A receptor stimulation was prevented by the mGlu2 receptor antagonist LY341495, while the LY379268-induced effect was abolished by the 5-HT2A receptor antagonist M100907.	LY 379268	175-183	5-hydroxytryptamine receptor 2A	Homo sapiens	220-235
30448990-6	2019	The effects of chronic LY379268 on 5-HT2A agonist-induced HTR were evaluated by treating mice with either vehicle or LY379268 (10 mg/kg) for 21 days and measuring 25CN-NBOH-induced HTR 48 h after the final LY379268 treatment.	LY 379268	23-31	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	35-41
30403408-7	2019	TLR3 activation also increased EtOH self-administration 18 days postinjection and enhanced the effects of the mGluR2/3 agonist LY379268 to reduce EtOH self-administration following poly(I:C).	LY 379268	127-135	toll-like receptor 3	Rattus norvegicus	0-4
30403408-7	2019	TLR3 activation also increased EtOH self-administration 18 days postinjection and enhanced the effects of the mGluR2/3 agonist LY379268 to reduce EtOH self-administration following poly(I:C).	LY 379268	127-135	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	110-116
30909243-12	2019	The current study builds upon previous research demonstrating hyperglutamatergic hippocampal signaling in AbetaPP/PS1 mice; however, long-term therapeutic efficacy of LY379268 in AbetaPP/PS1 was not observed.	LY 379268	167-175	presenilin 1	Mus musculus	187-190
30038413-8	2019	We found that chronic clozapine treatment decreased via HDAC2 the capabilities of the mGlu2/3 receptor agonist LY379268 to activate G-proteins in the frontal cortex of mice.	LY 379268	111-119	histone deacetylase 2	Mus musculus	56-61
30038413-8	2019	We found that chronic clozapine treatment decreased via HDAC2 the capabilities of the mGlu2/3 receptor agonist LY379268 to activate G-proteins in the frontal cortex of mice.	LY 379268	111-119	glutamate receptor, metabotropic 3	Mus musculus	86-93
29462112-0	2018	Microinjection of the mGluR2/3 agonist, LY379268, into the nucleus accumbens attenuates extinction latencies and the reinstatement of morphine-induced conditioned place preference in rats.	LY 379268	40-48	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	22-28
29462112-4	2018	In this study, we evaluated the effects of mGluR2/3 agonist, LY379268, on the extinction and reinstatement of morphine-induced CPP, following its microinjection into the NAc.	LY 379268	61-69	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	43-49
29462112-8	2018	The intra-accumbal injection of the mGluR2/3 agonist, LY379268, significantly decreased the extinction latencies and reinstatement of morphine-induced CPP at higher doses.	LY 379268	54-62	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	36-42
27502475-6	2017	In vivo iontophoretic application of the mGluR2/3 agonists (2R, 4R)-APDC or LY379268 onto dlPFC Delay cells produced an inverted-U effect on working memory representation, with enhanced neuronal firing following low doses of mGluR2/3 agonists.	LY 379268	76-84	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	225-231
29599719-5	2018	In addition, the mGlu2/3 receptor agonist LY379268, and the mGlu2 receptor positive allosteric modulator (PAM) CBiPES, potently blocked the HTR to DOI in WT and mGlu3 receptor KO mice.	LY 379268	42-50	glutamate receptor, metabotropic 3	Mus musculus	17-24
29599719-5	2018	In addition, the mGlu2/3 receptor agonist LY379268, and the mGlu2 receptor positive allosteric modulator (PAM) CBiPES, potently blocked the HTR to DOI in WT and mGlu3 receptor KO mice.	LY 379268	42-50	glutamate receptor, metabotropic 3	Mus musculus	161-166
29220747-7	2018	Systemic administration of the mGluR2/3 agonist LY37 significantly reduced ethanol- and sucrose-seeking.	LY 379268	48-52	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	31-37
28967122-8	2017	Incubation of cortical synaptosomes with anti-mGlu2 antibody prevented the LY379268-induced inhibition of glutamate exocytosis, and this response was partially reduced by the anti-mGlu3 antibody.	LY 379268	75-83	glutamate receptor, metabotropic 3	Mus musculus	180-185
28967122-9	2017	Incubation of spinal cord synaptosomes with the anti-mGlu3 antibody abolished LY379268-mediated reduction of glutamate exocytosis from these terminals, while the anti-mGlu2 antibody was inactive.	LY 379268	78-86	glutamate receptor, metabotropic 3	Mus musculus	53-58
28664928-7	2017	Finally, systemic administration of the mGlu2/3 agonist LY379268 disrupted contextual fear memory in a manner similar to the effect of the betaAR antagonist propranolol, and this effect was reversed by the mGlu3-negative allosteric modulator VU0650786.	LY 379268	56-64	glutamate receptor, metabotropic 3	Mus musculus	206-211
29562588-7	2018	Rats were injected intraperitoneally with the mGluR2/3 agonist LY379268 24 or 1 h before H-I (5 mg/kg).	LY 379268	63-71	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	46-52
28495373-2	2017	We recently showed that metabotropic glutamate receptor 3 (mGlu3R) activation by LY379268 promotes non-amyloidogenic cleavage of amyloid precursor protein (APP) in cultured astrocytes, leading to increased release of neuroprotective sAPPalpha.	LY 379268	81-89	amyloid beta (A4) precursor protein	Mus musculus	129-154
28495373-2	2017	We recently showed that metabotropic glutamate receptor 3 (mGlu3R) activation by LY379268 promotes non-amyloidogenic cleavage of amyloid precursor protein (APP) in cultured astrocytes, leading to increased release of neuroprotective sAPPalpha.	LY 379268	81-89	glutamate receptor, metabotropic 3	Mus musculus	24-57
28495373-7	2017	LY379268 induced brain-derived neurotrophic factor (BDNF) expression in astrocytes, and neutralizing BDNF from conditioned medium also prevented its neuroprotective effect on Abeta neurotoxicity.	LY 379268	0-8	brain derived neurotrophic factor	Mus musculus	17-50
28495373-7	2017	LY379268 induced brain-derived neurotrophic factor (BDNF) expression in astrocytes, and neutralizing BDNF from conditioned medium also prevented its neuroprotective effect on Abeta neurotoxicity.	LY 379268	0-8	brain derived neurotrophic factor	Mus musculus	52-56
28137451-13	2017	Pharmacological activation of mGluR2/3s with LY379268 also preferentially decreased the motivation to take cocaine in rats previously exposed to rapid drug injections.	LY 379268	45-53	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	30-36
23948211-0	2013	The reversal of cognitive, but not negative or positive symptoms of schizophrenia, by the mGlu2/3 receptor agonist, LY379268, is 5-HT1A dependent.	LY 379268	116-124	5-hydroxytryptamine receptor 1A	Homo sapiens	129-135
26149611-2	2016	The prototypical mGluR2/3 agonist, LY379268, has been shown to attenuate nicotine reinforcement and cue-induced reinstatement of drug seeking in rats, as well as reinstatement induced by drug-associated stimuli and contexts across different drugs of abuse (i.e., cocaine, heroin, and methamphetamine).	LY 379268	35-43	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	17-23
26861891-0	2016	mGluR2/3 agonist LY379268 rescues NMDA and GABAA receptor level deficits induced in a two-hit mouse model of schizophrenia.	LY 379268	17-25	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	0-6
26861891-4	2016	OBJECTIVES: We aimed to investigate the ability of a novel mGluR2/3 agonist, LY379268, to modulate the availability of the excitatory N-methyl-D-aspartate receptor (NMDA-R) and the inhibitory gamma-aminobutyrate-A receptor (GABAA-R), in a two-hit mouse model of schizophrenia.	LY 379268	77-85	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	59-65
26861891-4	2016	OBJECTIVES: We aimed to investigate the ability of a novel mGluR2/3 agonist, LY379268, to modulate the availability of the excitatory N-methyl-D-aspartate receptor (NMDA-R) and the inhibitory gamma-aminobutyrate-A receptor (GABAA-R), in a two-hit mouse model of schizophrenia.	LY 379268	77-85	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	134-163
26861891-4	2016	OBJECTIVES: We aimed to investigate the ability of a novel mGluR2/3 agonist, LY379268, to modulate the availability of the excitatory N-methyl-D-aspartate receptor (NMDA-R) and the inhibitory gamma-aminobutyrate-A receptor (GABAA-R), in a two-hit mouse model of schizophrenia.	LY 379268	77-85	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	165-171
26861891-4	2016	OBJECTIVES: We aimed to investigate the ability of a novel mGluR2/3 agonist, LY379268, to modulate the availability of the excitatory N-methyl-D-aspartate receptor (NMDA-R) and the inhibitory gamma-aminobutyrate-A receptor (GABAA-R), in a two-hit mouse model of schizophrenia.	LY 379268	77-85	gamma-aminobutyric acid (GABA) A receptor, subunit gamma 2	Mus musculus	192-222
26861891-4	2016	OBJECTIVES: We aimed to investigate the ability of a novel mGluR2/3 agonist, LY379268, to modulate the availability of the excitatory N-methyl-D-aspartate receptor (NMDA-R) and the inhibitory gamma-aminobutyrate-A receptor (GABAA-R), in a two-hit mouse model of schizophrenia.	LY 379268	77-85	gamma-aminobutyric acid (GABA) A receptor, subunit gamma 2	Mus musculus	224-231
26861891-9	2016	Acute treatment with LY379268 restored NMDA-R and GABAA-R levels in the two-hit mouse model comparable to olanzapine.	LY 379268	21-29	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	39-45
26861891-9	2016	Acute treatment with LY379268 restored NMDA-R and GABAA-R levels in the two-hit mouse model comparable to olanzapine.	LY 379268	21-29	gamma-aminobutyric acid (GABA) A receptor, subunit gamma 2	Mus musculus	50-57
26861891-10	2016	CONCLUSIONS: We demonstrate that the mGluR2/3 agonist LY379268 restores excitatory and inhibitory deficits with similar efficiency as olanzapine in our two-hit schizophrenia mouse model.	LY 379268	54-62	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	37-43
26955838-0	2016	Erratum to: mGluR2/3 agonist LY379268 rescues NMDA and GABAA receptor level deficits induced in a two-hit mouse model of schizophrenia.	LY 379268	29-37	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	12-18
26241341-0	2015	Nucleus accumbens injections of the mGluR2/3 agonist LY379268 increase cue-induced sucrose seeking following adult, but not adolescent sucrose self-administration.	LY 379268	53-61	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	36-42
26241341-6	2015	Following 21 days of abstinence, rats received microinjections of the mGluR2/3 agonist LY379268 (0.3 or 1.0 mug/side) or vehicle into the nucleus accumbens core, and 15 min later cue-induced sucrose seeking was assessed.	LY 379268	87-95	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	70-76
26241341-9	2015	On abstinence day 22, local injection of the mGluR2/3 agonist LY379268 increased cue-induced sucrose seeking only in adult rats, and had no effect in adolescents.	LY 379268	62-70	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	45-51
26142564-8	2015	Pretreatment with the mGluR2/3 agonist LY379268 (1.0-3.0 mg/kg; IP), but not the mGluR2/3 antagonist (0.3-1.0 mg/kg; IP), restored sensitivity to alcohol.	LY 379268	39-47	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	22-28
25063582-4	2014	Among the few proteins that were differentially influenced by the two drugs, Rab GDP dissociation inhibitor-beta (Rab GDIbeta) was down-regulated by LY379268 and showed a trend to an up-regulation in response to LY354740.	LY 379268	149-157	guanosine diphosphate (GDP) dissociation inhibitor 2	Mus musculus	77-112
25063582-4	2014	Among the few proteins that were differentially influenced by the two drugs, Rab GDP dissociation inhibitor-beta (Rab GDIbeta) was down-regulated by LY379268 and showed a trend to an up-regulation in response to LY354740.	LY 379268	149-157	guanosine diphosphate (GDP) dissociation inhibitor 2	Mus musculus	114-125
24650558-7	2014	The latter effect depended on 5-HT1A and 5-HT2A receptor activation and was reversed by haloperidol, clozapine, risperidone, and the mGlu2/3 agonist LY379268.	LY 379268	149-157	5-hydroxytryptamine receptor 1A	Rattus norvegicus	30-42
23958449-6	2013	Moreover, activation of mGluR2/3 receptors by the selective group II metabotropic receptor agonist LY379268 abolished BDNF-induced cognitive enhancement suggesting the involvement of presynaptic glutamatergic activity.	LY 379268	99-107	brain derived neurotrophic factor	Mus musculus	118-122
27207718-8	2016	No change in metabotropic glutamate receptor 2/3 (mGlu2/3) function was detected as bath application of the mGlu2/3 agonist LY379268 decreased spontaneous and miniature EPSC frequency in slices from both control and ethanol-consuming rats.	LY 379268	124-132	glutamate receptor, metabotropic 3	Mus musculus	108-115
25434487-2	2015	Activation of group II metabotropic glutamate (mGlu) receptors with the orthosteric agonist, LY379268, enhanced GDNF levels in cultured spinal cord astrocytes from wild-type mice and mGlu2(-/-) mice, but not in astrocytes from mGlu3(-/-) mice.	LY 379268	93-101	glial cell line derived neurotrophic factor	Mus musculus	112-116
25434487-2	2015	Activation of group II metabotropic glutamate (mGlu) receptors with the orthosteric agonist, LY379268, enhanced GDNF levels in cultured spinal cord astrocytes from wild-type mice and mGlu2(-/-) mice, but not in astrocytes from mGlu3(-/-) mice.	LY 379268	93-101	glutamate receptor, metabotropic 3	Mus musculus	227-232
25434487-3	2015	LY379268 protected Sternberger monoclonal incorporated antibody-32 (SMI-32)(+) motor neurons against excitotoxic death in mixed cultures of spinal cord cells, and its action was abrogated by anti-GDNF antibodies.	LY 379268	0-8	glial cell line derived neurotrophic factor	Mus musculus	196-200
25434487-8	2015	Continuous infusion of LY379268 also enhanced the expression of the glutamate transporter GLT-1, in the spinal cord.	LY 379268	23-31	solute carrier family 1 (glial high affinity glutamate transporter), member 2	Mus musculus	90-95
25434487-10	2015	Continuous treatment with 1 or 5mg/kg/day with LY379268 had a beneficial effect on neurological disability in SOD1G93A mice.	LY 379268	47-55	superoxide dismutase 1, soluble	Mus musculus	110-114
25434487-11	2015	At day 40 of treatment, LY379268 enhanced spinal cord levels of GDNF and GLT-1, and rescued spinal cord motor neurons, as assessed by stereologic counting of SMI-32(+) cells.	LY 379268	24-32	glial cell line derived neurotrophic factor	Mus musculus	64-68
25434487-11	2015	At day 40 of treatment, LY379268 enhanced spinal cord levels of GDNF and GLT-1, and rescued spinal cord motor neurons, as assessed by stereologic counting of SMI-32(+) cells.	LY 379268	24-32	solute carrier family 1 (glial high affinity glutamate transporter), member 2	Mus musculus	73-78
24859609-4	2014	LY379268 is a selective mGlu2/3 receptor agonist that has shown to be effective in several animal models of stroke, epilepsy, and drug abuse.	LY 379268	0-8	glutamate receptor, metabotropic 3	Mus musculus	24-31
24859609-15	2014	The present data show that the mGlu2/3 receptor agonist LY379268 reversed non-spatial, but not spatial, recognition memory deficits induced by NMDA receptor blockade or DA receptor agonism in rodents.	LY 379268	56-64	glutamate receptor, metabotropic 3	Mus musculus	31-38
24291464-4	2014	In the present study, we used the dual mGlu2/3 receptor agonist LY379268, which in pure astrocyte cultures selectively activates mGlu3 receptor subtype since mGlu2 receptor subtype is not expressed by these cells.	LY 379268	64-72	glutamate receptor, metabotropic 3	Mus musculus	129-134
24291464-6	2014	LY379268-induced increase of PPAR-gamma levels could be involved in the effect of the agonist on sAPPalpha release.	LY 379268	0-8	peroxisome proliferator activated receptor gamma	Mus musculus	29-39
24067300-9	2014	In contrast, reducing glutamatergic transmission in the NAc via bilateral injections of the metabotropic glutamate receptor-2/3 agonist LY379268 reduced drinking in dependent (EtOH) mice to nondependent (CTL) levels, whereas having a more modest effect in decreasing ethanol consumption in CTL mice.	LY 379268	136-144	glutamate receptor, metabotropic 2	Mus musculus	92-125
24206109-4	2014	These reductions were effectively restored by mGluR2/3 activation with mGluR2/3 agonists, LY379268 or DCG-IV, after the 6 h OGD insult.	LY 379268	90-98	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	46-52
24099265-7	2013	The mGluR2/3 agonist, LY379268, which itself is unable to restore NOR in the scNMDAR-treated rodents, can also restore NOR when given with lurasidone, an AAPD.	LY 379268	22-30	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	4-10
23948211-5	2013	Here, we decided to investigate the involvement of 5-HT1A receptors in the LY379268-induced antipsychotic effects.	LY 379268	75-83	5-hydroxytryptamine receptor 1A	Homo sapiens	51-57
22659408-3	2013	The selective mGluR2/3 agonist LY379268 inhibited the K(+)-evoked overflow of [(3)H]glycine in a concentration-dependent manner (EC(50) about 0.2 nM).	LY 379268	31-39	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	14-20
23624743-7	2013	Indeed, addict-like rats that were treated systemically with the mGluR2/3 agonist LY379268 (0, 0.3, and 3 mg/kg) showed a pronounced reduction in cue-induced reinstatement of cocaine-seeking.	LY 379268	82-90	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	65-71
23593498-2	2013	Here we examined the effects of LY379268 (LY37) on the expression and trafficking of the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptor subunits GluA1 and GluA2 in prefrontal neurons.	LY 379268	32-40	glutamate ionotropic receptor AMPA type subunit 1	Homo sapiens	168-173
23593498-2	2013	Here we examined the effects of LY379268 (LY37) on the expression and trafficking of the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptor subunits GluA1 and GluA2 in prefrontal neurons.	LY 379268	32-36	glutamate ionotropic receptor AMPA type subunit 1	Homo sapiens	168-173
23593498-3	2013	We show that LY37 significantly increased the surface and total expression of both GluA1 and GluA2 subunits in cultured prefrontal neurons and in vivo.	LY 379268	13-17	glutamate ionotropic receptor AMPA type subunit 1	Homo sapiens	83-88
23593498-3	2013	We show that LY37 significantly increased the surface and total expression of both GluA1 and GluA2 subunits in cultured prefrontal neurons and in vivo.	LY 379268	13-17	glutamate ionotropic receptor AMPA type subunit 2	Homo sapiens	93-98
23593498-10	2013	Further, LY37 significantly increased the phosphorylation, but not total protein, of extracellular signal-regulated kinase 1/2 (ERK1/2).	LY 379268	9-13	mitogen-activated protein kinase 1	Homo sapiens	85-126
23593498-10	2013	Further, LY37 significantly increased the phosphorylation, but not total protein, of extracellular signal-regulated kinase 1/2 (ERK1/2).	LY 379268	9-13	mitogen-activated protein kinase 3	Homo sapiens	128-134
23827202-4	2013	Systemic injections of LY379268, AMN082, and MMPIP prior to conditioning decreased the acquisition of CTA, revealing that mGlu2/3 and mGlu7 are involved in CTA learning.	LY 379268	23-31	glutamate receptor, metabotropic 3	Mus musculus	122-129
23624743-0	2013	The mGluR2/3 agonist LY379268 induced anti-reinstatement effects in rats exhibiting addiction-like behavior.	LY 379268	21-29	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	4-10
22659408-4	2013	The effect of LY379268 was prevented by the selective mGluR2/3 antagonist LY341495 (IC(50) about 1 nM).	LY 379268	14-22	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	54-60
22659409-0	2013	Attenuation of methamphetamine seeking by the mGluR2/3 agonist LY379268 in rats with histories of restricted and escalated self-administration.	LY 379268	63-71	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	46-52
22659409-3	2013	Following self-administration and subsequent extinction training, rats were pretreated with the selective mGluR(2/3) agonist LY379268 (variable dose, 0-3 mg/kg), exposed to METH-paired cues or a priming injection of METH (1 mg/kg), and tested for reinstatement of METH-seeking behavior.	LY 379268	125-133	glutamate receptor, metabotropic 2	Mus musculus	106-115
21881571-0	2011	Enhanced sensitivity to attenuation of conditioned reinstatement by the mGluR 2/3 agonist LY379268 and increased functional activity of mGluR 2/3 in rats with a history of ethanol dependence.	LY 379268	90-98	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	72-79
22659409-5	2013	However, LgA rats demonstrated greater sensitivity to mGluR(2/3) stimulation with attenuated responding during cue-induced reinstatement after 0.3 mg/kg and higher doses of LY379268, whereas ShA rats decreased cue-induced reinstatement behavior following 1.0 mg/kg and 3.0 mg/kg LY379268.	LY 379268	173-181	glutamate receptor, metabotropic 2	Mus musculus	54-63
22659409-5	2013	However, LgA rats demonstrated greater sensitivity to mGluR(2/3) stimulation with attenuated responding during cue-induced reinstatement after 0.3 mg/kg and higher doses of LY379268, whereas ShA rats decreased cue-induced reinstatement behavior following 1.0 mg/kg and 3.0 mg/kg LY379268.	LY 379268	279-287	glutamate receptor, metabotropic 2	Mus musculus	54-63
22820300-0	2012	BDNF may play a differential role in the protective effect of the mGluR2/3 agonist LY379268 on striatal projection neurons in R6/2 Huntington"s disease mice.	LY 379268	83-91	brain derived neurotrophic factor	Mus musculus	0-4
22820300-0	2012	BDNF may play a differential role in the protective effect of the mGluR2/3 agonist LY379268 on striatal projection neurons in R6/2 Huntington"s disease mice.	LY 379268	83-91	glutamate receptor, metabotropic 2	Mus musculus	66-74
22820300-1	2012	We have found that daily subcutaneous injection with a maximum tolerated dose (MTD) of the mGluR2/3 agonist LY379268 (20mg/kg) beginning at 4 weeks dramatically improves the phenotype in R6/2 mice.	LY 379268	108-116	glutamate receptor, metabotropic 2	Mus musculus	91-99
22820300-4	2012	We found that LY379268 increased BDNF expression in layer 5 neurons in motor cortex, which project to striatum, partly rescued a preferential loss of enkephalinergic striatal neurons, and enhanced substance P (SP) expression by SP striatal projection neurons.	LY 379268	14-22	brain derived neurotrophic factor	Mus musculus	33-37
22820300-6	2012	Thus, LY379268 may protect the two main striatal projection neuron types by different mechanisms, enkephalinergic neurons by the trophic benefit of BDNF, and SP neurons by a mechanism not involving BDNF.	LY 379268	6-14	brain derived neurotrophic factor	Mus musculus	148-152
21863235-0	2012	Pre-treatment with the mGlu2/3 receptor agonist LY379268 attenuates DOI-induced impulsive responding and regional c-Fos protein expression.	LY 379268	48-56	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	114-119
21863235-8	2012	DOI enhanced Fos IR within fronto-cortical and limbic brain structures, and this effect was blocked by LY379268 pre-treatment.	LY 379268	103-111	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	13-16
21863235-9	2012	Double immunofluorescence labeling showed a specific co-localization of DOI-elicited Fos IR with GABAergic (GAD(67)-positive) cells lacking the calcium-binding protein parvalbumin while LY379268 increased Fos IR in GABAergic and non-GABAergic cells.	LY 379268	186-194	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	85-88
26317098-0	2013	The mGlu2/3 Receptor Agonists LY354740 and LY379268 Differentially Regulate Restraint-Stress-Induced Expression of c-Fos in Rat Cerebral Cortex.	LY 379268	43-51	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	115-120
26317098-3	2013	We compared the efficacy of LY354740 and LY379268 in attenuating restraint-stress-induced expression of the immediate early gene c-Fos in the rat prelimbic (PrL) and infralimbic (IL) cortex.	LY 379268	41-49	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	129-134
26317098-7	2013	Because both compounds inhibit serotonin 2A receptor (5-HT2AR)-induced c-Fos expression, we hypothesize that LY354740 and LY379268 have different in vivo properties and that 5-HT2AR activation and restraint stress induce c-Fos through distinct mechanisms.	LY 379268	122-130	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	71-76
22472187-2	2012	Since corticostriatal terminals possess mGluR2/3 autoreceptors, whose activation dampens glutamate release, we tested the ability of the mGluR2/3 agonist LY379268 to improve the phenotype in R6/2 HD mice with 120-125 CAG repeats.	LY 379268	154-162	glutamate receptor, metabotropic 2	Mus musculus	137-145
22388870-8	2012	Pretreatment with the mGluR2/3 agonist LY379268 completely blocked potentiation of both synaptic strength and intrinsic excitability.	LY 379268	39-47	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	22-28
22091727-8	2011	RO4491533 appeared to engage the central mGluR2 and mGluR3 receptors since the compound reversed the hypolocomotor effect of an mGluR2/3 orthosteric agonist LY379268 in a target-specific manner, as did the group II orthosteric mGluR2/3 antagonist LY341495.	LY 379268	157-165	glutamate receptor, ionotropic, AMPA3 (alpha 3)	Mus musculus	52-58
22091727-8	2011	RO4491533 appeared to engage the central mGluR2 and mGluR3 receptors since the compound reversed the hypolocomotor effect of an mGluR2/3 orthosteric agonist LY379268 in a target-specific manner, as did the group II orthosteric mGluR2/3 antagonist LY341495.	LY 379268	157-165	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	128-134
22091727-8	2011	RO4491533 appeared to engage the central mGluR2 and mGluR3 receptors since the compound reversed the hypolocomotor effect of an mGluR2/3 orthosteric agonist LY379268 in a target-specific manner, as did the group II orthosteric mGluR2/3 antagonist LY341495.	LY 379268	157-165	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	128-134
21881571-6	2011	The mGluR(2/3) agonist LY379268 dose -dependently reduced reinstatement in all groups, but was more effective at low doses in the SW and RW groups.	LY 379268	23-31	glutamate receptor, metabotropic 2	Mus musculus	4-13
21734651-4	2011	In male Long-Evans rats trained to discriminate between alcohol (1 g/kg, IG) and water, the mGlu2/3 agonist LY379268 (0.3-10 mg/kg) did not produce alcohol-like stimulus effects.	LY 379268	108-116	glutamate receptor, metabotropic 3	Mus musculus	92-99
21619889-0	2011	mGluR2/3 agonist LY379268, by enhancing the production of GDNF, induces a time-related phosphorylation of RET receptor and intracellular signaling Erk1/2 in mouse striatum.	LY 379268	17-25	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	0-6
21619889-0	2011	mGluR2/3 agonist LY379268, by enhancing the production of GDNF, induces a time-related phosphorylation of RET receptor and intracellular signaling Erk1/2 in mouse striatum.	LY 379268	17-25	glial cell line derived neurotrophic factor	Mus musculus	58-62
21619889-0	2011	mGluR2/3 agonist LY379268, by enhancing the production of GDNF, induces a time-related phosphorylation of RET receptor and intracellular signaling Erk1/2 in mouse striatum.	LY 379268	17-25	ret proto-oncogene	Mus musculus	106-109
21619889-0	2011	mGluR2/3 agonist LY379268, by enhancing the production of GDNF, induces a time-related phosphorylation of RET receptor and intracellular signaling Erk1/2 in mouse striatum.	LY 379268	17-25	mitogen-activated protein kinase 3	Mus musculus	147-153
21619889-1	2011	In the present study we aimed to verify if the enhancement of glial cell line-derived neurotrophic factor (GDNF) production in mouse striatum following treatment with LY379268 may also induce in the nigrostriatal system a time-related activation of RET receptor and its specific intracellular signaling.	LY 379268	167-175	glial cell line derived neurotrophic factor	Mus musculus	62-105
21619889-1	2011	In the present study we aimed to verify if the enhancement of glial cell line-derived neurotrophic factor (GDNF) production in mouse striatum following treatment with LY379268 may also induce in the nigrostriatal system a time-related activation of RET receptor and its specific intracellular signaling.	LY 379268	167-175	glial cell line derived neurotrophic factor	Mus musculus	107-111
21619889-1	2011	In the present study we aimed to verify if the enhancement of glial cell line-derived neurotrophic factor (GDNF) production in mouse striatum following treatment with LY379268 may also induce in the nigrostriatal system a time-related activation of RET receptor and its specific intracellular signaling.	LY 379268	167-175	ret proto-oncogene	Mus musculus	249-252
21619889-2	2011	For this purpose, we have investigated the effects of LY379268 treatment on RET phosphorylation at the Tyr1062 and on downstream signaling Erk1/2, Akt and PLCgamma1 pathway activation.	LY 379268	54-62	ret proto-oncogene	Mus musculus	76-79
21619889-2	2011	For this purpose, we have investigated the effects of LY379268 treatment on RET phosphorylation at the Tyr1062 and on downstream signaling Erk1/2, Akt and PLCgamma1 pathway activation.	LY 379268	54-62	mitogen-activated protein kinase 3	Mus musculus	139-145
21619889-2	2011	For this purpose, we have investigated the effects of LY379268 treatment on RET phosphorylation at the Tyr1062 and on downstream signaling Erk1/2, Akt and PLCgamma1 pathway activation.	LY 379268	54-62	thymoma viral proto-oncogene 1	Mus musculus	147-150
21619889-2	2011	For this purpose, we have investigated the effects of LY379268 treatment on RET phosphorylation at the Tyr1062 and on downstream signaling Erk1/2, Akt and PLCgamma1 pathway activation.	LY 379268	54-62	phospholipase C, gamma 1	Mus musculus	155-164
21619889-3	2011	The results showed that treatment with LY379268 (3 mg/kg) induces a significant increase of GDNF levels and time-related RET and Erk1/2 phosphorylation in the striatum.	LY 379268	39-47	glial cell line derived neurotrophic factor	Mus musculus	92-96
21619889-3	2011	The results showed that treatment with LY379268 (3 mg/kg) induces a significant increase of GDNF levels and time-related RET and Erk1/2 phosphorylation in the striatum.	LY 379268	39-47	ret proto-oncogene	Mus musculus	121-124
21619889-3	2011	The results showed that treatment with LY379268 (3 mg/kg) induces a significant increase of GDNF levels and time-related RET and Erk1/2 phosphorylation in the striatum.	LY 379268	39-47	mitogen-activated protein kinase 3	Mus musculus	129-135
21619889-7	2011	A complete block of LY379268 effect on striatal RET and p-Erk1/2 phosphorylation was observed in mice intrastriatal injected with anti-GDNF antibodies, suggesting a correlation between GDNF upregulation and RET activation.	LY 379268	20-28	ret proto-oncogene	Mus musculus	48-51
21619889-7	2011	A complete block of LY379268 effect on striatal RET and p-Erk1/2 phosphorylation was observed in mice intrastriatal injected with anti-GDNF antibodies, suggesting a correlation between GDNF upregulation and RET activation.	LY 379268	20-28	mitogen-activated protein kinase 3	Mus musculus	58-64
21619889-7	2011	A complete block of LY379268 effect on striatal RET and p-Erk1/2 phosphorylation was observed in mice intrastriatal injected with anti-GDNF antibodies, suggesting a correlation between GDNF upregulation and RET activation.	LY 379268	20-28	glial cell line derived neurotrophic factor	Mus musculus	135-139
21619889-7	2011	A complete block of LY379268 effect on striatal RET and p-Erk1/2 phosphorylation was observed in mice intrastriatal injected with anti-GDNF antibodies, suggesting a correlation between GDNF upregulation and RET activation.	LY 379268	20-28	glial cell line derived neurotrophic factor	Mus musculus	185-189
21619889-7	2011	A complete block of LY379268 effect on striatal RET and p-Erk1/2 phosphorylation was observed in mice intrastriatal injected with anti-GDNF antibodies, suggesting a correlation between GDNF upregulation and RET activation.	LY 379268	20-28	ret proto-oncogene	Mus musculus	207-210
21619889-8	2011	Overall, with present data we have shown that activation of mGluR2/3 receptors by LY379268 may be particularly promising for nigrostriatal dopaminergic system protection by enhancing striatal levels of GDNF/RET trophic system activity.	LY 379268	82-90	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	60-66
21619889-8	2011	Overall, with present data we have shown that activation of mGluR2/3 receptors by LY379268 may be particularly promising for nigrostriatal dopaminergic system protection by enhancing striatal levels of GDNF/RET trophic system activity.	LY 379268	82-90	glial cell line derived neurotrophic factor	Mus musculus	202-206
21619889-8	2011	Overall, with present data we have shown that activation of mGluR2/3 receptors by LY379268 may be particularly promising for nigrostriatal dopaminergic system protection by enhancing striatal levels of GDNF/RET trophic system activity.	LY 379268	82-90	ret proto-oncogene	Mus musculus	207-210
21654734-1	2011	The metabotropic glutamate 2/3 (mGlu2/3) receptor agonist LY379268 ([-]-2-oxa-4-aminobicyclo [3.1.0] hexane-4,6-dicarboxylate) attenuates both nicotine self-administration and cue-induced nicotine seeking in rats.	LY 379268	58-66	glutamate receptor, metabotropic 3	Mus musculus	32-39
21734651-8	2011	Intra-amygdala activation of mGlu2/3 receptors by LY379268 (6 mug) inhibited the discriminative stimulus effects of alcohol, without altering response rate.	LY 379268	50-58	glutamate receptor, metabotropic 3	Mus musculus	29-36
21477044-3	2011	Western blotting revealed increases in phosphorylated Akt (pAkt) and phosphorylated glycogen synthase kinase-3 (pGSK-3) following acute and repeated treatment of LY379268 (mGlu(2/3) agonist), whereas increases in dishevelled-2 (Dvl-2), dishevelled-3 (Dvl-3), GSK-3 and beta-catenin were only observed following repeated treatment.	LY 379268	162-170	dishevelled segment polarity protein 3	Homo sapiens	251-256
21432027-4	2011	OBJECTIVES AND METHODS: We tested the hypotheses that the mGlu2/3 agonist, LY379268, by itself, or in combination with APDs or pimavanserin, a 5-HT(2A) inverse agonist, would reverse the deficit in NOR induced by subchronic treatment with PCP (2 mg/kg, b.i.d., for 7 days).	LY 379268	75-83	glutamate receptor, metabotropic 3	Mus musculus	58-65
21505039-6	2011	Treatment with LY379268 also increased the amount of Gadd45-beta bound to specific promoter regions of reelin, brain-derived neurotrophic factor (BDNF), and glutamate decarboxylase-67 (GAD67).	LY 379268	15-23	brain derived neurotrophic factor	Mus musculus	111-144
21505039-6	2011	Treatment with LY379268 also increased the amount of Gadd45-beta bound to specific promoter regions of reelin, brain-derived neurotrophic factor (BDNF), and glutamate decarboxylase-67 (GAD67).	LY 379268	15-23	brain derived neurotrophic factor	Mus musculus	146-150
21505039-10	2011	The action of LY379268 on Gadd45-beta was mimicked by valproate and clozapine but not haloperidol.	LY 379268	14-22	growth arrest and DNA-damage-inducible 45 beta	Mus musculus	26-37
21477044-0	2011	Regulation of Akt and Wnt signaling by the group II metabotropic glutamate receptor antagonist LY341495 and agonist LY379268.	LY 379268	116-124	AKT serine/threonine kinase 1	Homo sapiens	14-17
21477044-3	2011	Western blotting revealed increases in phosphorylated Akt (pAkt) and phosphorylated glycogen synthase kinase-3 (pGSK-3) following acute and repeated treatment of LY379268 (mGlu(2/3) agonist), whereas increases in dishevelled-2 (Dvl-2), dishevelled-3 (Dvl-3), GSK-3 and beta-catenin were only observed following repeated treatment.	LY 379268	162-170	catenin beta 1	Homo sapiens	269-281
21477044-0	2011	Regulation of Akt and Wnt signaling by the group II metabotropic glutamate receptor antagonist LY341495 and agonist LY379268.	LY 379268	116-124	Wnt family member 1	Homo sapiens	22-25
21477044-3	2011	Western blotting revealed increases in phosphorylated Akt (pAkt) and phosphorylated glycogen synthase kinase-3 (pGSK-3) following acute and repeated treatment of LY379268 (mGlu(2/3) agonist), whereas increases in dishevelled-2 (Dvl-2), dishevelled-3 (Dvl-3), GSK-3 and beta-catenin were only observed following repeated treatment.	LY 379268	162-170	AKT serine/threonine kinase 1	Homo sapiens	54-57
21477044-6	2011	However, there was no association between the mGlu(2/3) complex and Akt suggesting that changes in Akt signaling following LY341495 and LY379268 treatments may not be directly mediated by the mGlu(2/3) .	LY 379268	136-144	AKT serine/threonine kinase 1	Homo sapiens	99-102
21477044-3	2011	Western blotting revealed increases in phosphorylated Akt (pAkt) and phosphorylated glycogen synthase kinase-3 (pGSK-3) following acute and repeated treatment of LY379268 (mGlu(2/3) agonist), whereas increases in dishevelled-2 (Dvl-2), dishevelled-3 (Dvl-3), GSK-3 and beta-catenin were only observed following repeated treatment.	LY 379268	162-170	glutamate receptor, metabotropic 3	Mus musculus	172-180
21326193-3	2011	We found that the mGluR2/3 agonist LY379268 effectively recovered the disrupted expression of NMDA receptors induced by MK-801 administration.	LY 379268	35-43	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	18-24
21477044-3	2011	Western blotting revealed increases in phosphorylated Akt (pAkt) and phosphorylated glycogen synthase kinase-3 (pGSK-3) following acute and repeated treatment of LY379268 (mGlu(2/3) agonist), whereas increases in dishevelled-2 (Dvl-2), dishevelled-3 (Dvl-3), GSK-3 and beta-catenin were only observed following repeated treatment.	LY 379268	162-170	dishevelled segment polarity protein 2	Homo sapiens	213-226
21477044-3	2011	Western blotting revealed increases in phosphorylated Akt (pAkt) and phosphorylated glycogen synthase kinase-3 (pGSK-3) following acute and repeated treatment of LY379268 (mGlu(2/3) agonist), whereas increases in dishevelled-2 (Dvl-2), dishevelled-3 (Dvl-3), GSK-3 and beta-catenin were only observed following repeated treatment.	LY 379268	162-170	dishevelled segment polarity protein 2	Homo sapiens	228-233
21477044-3	2011	Western blotting revealed increases in phosphorylated Akt (pAkt) and phosphorylated glycogen synthase kinase-3 (pGSK-3) following acute and repeated treatment of LY379268 (mGlu(2/3) agonist), whereas increases in dishevelled-2 (Dvl-2), dishevelled-3 (Dvl-3), GSK-3 and beta-catenin were only observed following repeated treatment.	LY 379268	162-170	dishevelled segment polarity protein 3	Homo sapiens	236-249
21326193-4	2011	This effect was attributable to the direct regulatory action of LY379268 on NMDA receptors via activation of the Akt/GSK-3beta signaling pathway.	LY 379268	64-72	AKT serine/threonine kinase 1	Rattus norvegicus	113-116
21326193-4	2011	This effect was attributable to the direct regulatory action of LY379268 on NMDA receptors via activation of the Akt/GSK-3beta signaling pathway.	LY 379268	64-72	glycogen synthase kinase 3 beta	Rattus norvegicus	117-126
21193020-3	2011	The mGluR2/3 receptor agonist, LY379268, injected s.c. at 0.1 mg/kg, reduced (R)-CPP-induced impairment in attentional functioning (accuracy) and impulsivity but not compulsive perseveration.	LY 379268	31-39	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	4-10
21505039-5	2011	Induction of Gadd45-beta by LY379268 was abrogated by the mGlu2/3 receptor antagonist (2S)-2-amino-2-[(1S,2S)-2-carboxycycloprop-1-yl]-3-(xanth-9-yl) propanoic acid (LY341495; 1 mg/kg i.p.).	LY 379268	28-36	growth arrest and DNA-damage-inducible 45 beta	Mus musculus	13-24
21505039-6	2011	Treatment with LY379268 also increased the amount of Gadd45-beta bound to specific promoter regions of reelin, brain-derived neurotrophic factor (BDNF), and glutamate decarboxylase-67 (GAD67).	LY 379268	15-23	growth arrest and DNA-damage-inducible 45 beta	Mus musculus	53-64
21193020-5	2011	LY379268 at the dose effective in reducing (R)-CPP-induced behavioral deficit reduced both the (R)-CPP-induced rise in glutamate efflux in the prefrontal cortex and the increase in p-S(133)CREB in the frontal cortex but was without effect on the decrease in p-S(133)CREB in the caudate-putamen.	LY 379268	0-8	cAMP responsive element binding protein 1	Rattus norvegicus	189-193
21193020-5	2011	LY379268 at the dose effective in reducing (R)-CPP-induced behavioral deficit reduced both the (R)-CPP-induced rise in glutamate efflux in the prefrontal cortex and the increase in p-S(133)CREB in the frontal cortex but was without effect on the decrease in p-S(133)CREB in the caudate-putamen.	LY 379268	0-8	cAMP responsive element binding protein 1	Rattus norvegicus	266-270
21159998-7	2011	The dual mGlu2/3 receptor agonist, (-)-2-oxa-4-aminobicyclo[3.1.0]exhane-4,6-dicarboxylic acid (LY379268), was neuroprotective in mixed cultures via a paracrine mechanism mediated by transforming growth factor-beta1.	LY 379268	96-104	transforming growth factor beta 1	Homo sapiens	183-215
21172908-6	2011	Furthermore, pretreatment of LY379268 significantly attenuated ketamine-induced brain activation in a region-specific manner (posterior cingulate, entorhinal, and retrosplenial cortices, hippocampus CA1, and PAG).	LY 379268	29-37	carbonic anhydrase 1	Rattus norvegicus	199-202
21159998-8	2011	LY379268 lost its protective activity in neurons grown with astrocytes lacking mGlu3 receptors, indicating that protection against Abeta neurotoxicity was mediated entirely by glial mGlu3 receptors.	LY 379268	0-8	glutamate receptor, metabotropic 3	Mus musculus	79-84
21159998-8	2011	LY379268 lost its protective activity in neurons grown with astrocytes lacking mGlu3 receptors, indicating that protection against Abeta neurotoxicity was mediated entirely by glial mGlu3 receptors.	LY 379268	0-8	glutamate receptor, metabotropic 3	Mus musculus	182-187
21779400-8	2011	In the present work, we showed that the cytoprotective effect of mGluR3 agonists (LY379268 and LY404039) requires both the reduction of intracellular cAMP levels and activation of Akt, as assessed by MTT and TUNEL techniques.	LY 379268	82-90	glutamate receptor, ionotropic, AMPA3 (alpha 3)	Mus musculus	65-71
20607219-0	2011	The mGluR2/3 agonist LY379268 reverses post-weaning social isolation-induced recognition memory deficits in the rat.	LY 379268	21-29	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	4-10
20607219-3	2011	OBJECTIVE: This study evaluated the potent, selective mGluR2/3 agonist, LY379268, on the behavioural deficits induced by rearing rat pups in social isolation from weaning, a neurodevelopmental model of schizophrenia, to investigate its antipsychotic potential.	LY 379268	72-80	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	54-60
20607219-9	2011	CONCLUSIONS: These data show that LY379268 can reverse some, but not all, post-weaning social isolation-induced changes which have translational relevance to core symptom defects in schizophrenia and support a potential therapeutic role of mGluR2/3 agonists in its treatment.	LY 379268	34-42	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	240-246
21326193-5	2011	As occurs with the antipsychotic drug clozapine, acute treatment with LY379268 significantly increased the expression and phosphorylation of NMDA receptors, as well as Akt and GSK-3beta.	LY 379268	70-78	AKT serine/threonine kinase 1	Rattus norvegicus	168-171
21326193-5	2011	As occurs with the antipsychotic drug clozapine, acute treatment with LY379268 significantly increased the expression and phosphorylation of NMDA receptors, as well as Akt and GSK-3beta.	LY 379268	70-78	glycogen synthase kinase 3 beta	Rattus norvegicus	176-185
20831878-8	2011	Finally, mGluR2/3 agonists LY379268 and LY404039 also inhibited light-induced phase delays of activity rhythms.	LY 379268	27-35	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	9-15
21235748-7	2011	However tolerance to the analgesic effect of LY379268 (3 mg/kg, ip) in mGlu3-(/)- mice developed following 5 consecutive days of injection.Taken together, these results demonstrate that: (i) mGlu2 receptors play a predominant role over mGlu3 receptors in the control of inflammatory pain in mice; (ii) the analgesic activity of mixed mGlu2/3 agonists is entirely mediated by the activation of the mGlu2 subtype and (iii) the development of tolerance to the analgesic effect of mGlu2/3 agonists develops despite the lack of mGlu3 receptors.	LY 379268	45-53	glutamate receptor, metabotropic 3	Mus musculus	71-76
21235748-7	2011	However tolerance to the analgesic effect of LY379268 (3 mg/kg, ip) in mGlu3-(/)- mice developed following 5 consecutive days of injection.Taken together, these results demonstrate that: (i) mGlu2 receptors play a predominant role over mGlu3 receptors in the control of inflammatory pain in mice; (ii) the analgesic activity of mixed mGlu2/3 agonists is entirely mediated by the activation of the mGlu2 subtype and (iii) the development of tolerance to the analgesic effect of mGlu2/3 agonists develops despite the lack of mGlu3 receptors.	LY 379268	45-53	glutamate receptor, metabotropic 3	Mus musculus	236-241
21235748-7	2011	However tolerance to the analgesic effect of LY379268 (3 mg/kg, ip) in mGlu3-(/)- mice developed following 5 consecutive days of injection.Taken together, these results demonstrate that: (i) mGlu2 receptors play a predominant role over mGlu3 receptors in the control of inflammatory pain in mice; (ii) the analgesic activity of mixed mGlu2/3 agonists is entirely mediated by the activation of the mGlu2 subtype and (iii) the development of tolerance to the analgesic effect of mGlu2/3 agonists develops despite the lack of mGlu3 receptors.	LY 379268	45-53	glutamate receptor, metabotropic 3	Mus musculus	236-241
21779400-8	2011	In the present work, we showed that the cytoprotective effect of mGluR3 agonists (LY379268 and LY404039) requires both the reduction of intracellular cAMP levels and activation of Akt, as assessed by MTT and TUNEL techniques.	LY 379268	82-90	AKT serine/threonine kinase 1	Rattus norvegicus	180-183
21159980-10	2010	Reducing cortical excitability with the metabotropic glutamate receptor 2/3 agonist LY379268 (1 mg/kg, i.p.)	LY 379268	84-92	glutamate metabotropic receptor 2	Rattus norvegicus	40-73
20118184-9	2010	Treatment of the cultures with the mGluR2/3 agonist LY379268 to suppress corticostriatal glutamate release completely blocked spine loss in dopamine-denervated cultures.	LY 379268	52-60	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	35-41
20969570-6	2010	In addition significant reductions in extracellular glutamate were seen with locally applied omega-conotoxin (MVIIC; ~ 50%; calcium channel blocker), and the mGluR(2/3) agonist, LY379268 (~ 20%), and a significant increase with the mGluR(2/3) antagonist LY341495 (~ 40%), effects all consistent with a large neuronal contribution to the resting glutamate levels.	LY 379268	178-186	glutamate receptor, metabotropic 2	Mus musculus	158-167
20969570-6	2010	In addition significant reductions in extracellular glutamate were seen with locally applied omega-conotoxin (MVIIC; ~ 50%; calcium channel blocker), and the mGluR(2/3) agonist, LY379268 (~ 20%), and a significant increase with the mGluR(2/3) antagonist LY341495 (~ 40%), effects all consistent with a large neuronal contribution to the resting glutamate levels.	LY 379268	178-186	glutamate receptor, metabotropic 2	Mus musculus	232-241
20416862-12	2010	The differential behavioral effects of LY379268 and MTEP in rats with a history of long access to cocaine have implications for the treatment target potential of mGluR2/3 and mGluR5.	LY 379268	39-47	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	162-168
20416862-12	2010	The differential behavioral effects of LY379268 and MTEP in rats with a history of long access to cocaine have implications for the treatment target potential of mGluR2/3 and mGluR5.	LY 379268	39-47	glutamate receptor, ionotropic, kainate 1	Mus musculus	175-181
20132926-6	2010	In parallel, binge alcohol exposure suppressed TGF-beta expression in both the EC and dentate gyrus, whereas LY379268 increased TGF-beta in the EC only.	LY 379268	109-117	transforming growth factor, beta 1	Rattus norvegicus	128-136
20209633-4	2010	The mGluR2 and mGluR3 agonists LY379268, LY354740, and (2R,4R)-APDC increased the amplitude but decreased the frequency of spontaneous Ca(2+) spikes in cultured cortical neurons.	LY 379268	31-39	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	4-10
20209633-4	2010	The mGluR2 and mGluR3 agonists LY379268, LY354740, and (2R,4R)-APDC increased the amplitude but decreased the frequency of spontaneous Ca(2+) spikes in cultured cortical neurons.	LY 379268	31-39	glutamate receptor, ionotropic, AMPA3 (alpha 3)	Mus musculus	15-21
19897175-7	2010	By contrast, infusion of the mGluR2/3 agonist LY379268 in the nucleus accumbens reduced self-administration and produced nonspecific reductions in locomotor activity.	LY 379268	46-54	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	29-35
20091783-3	2010	Activation of mGlu3 receptors with LY379268 (100 nM, applied every other day), during the differentiation period, impaired astrocyte differentiation, favoring the maintenance in culture of proliferating progenitors co-expressing GFAP with the immature markers, Sox1 and nestin.	LY 379268	35-43	glutamate receptor, metabotropic 3	Mus musculus	14-19
20072121-0	2010	The mGluR2/3 agonist LY379268 blocks the effects of GLT-1 upregulation on prepulse inhibition of the startle reflex in adult rats.	LY 379268	21-29	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	4-10
20072121-0	2010	The mGluR2/3 agonist LY379268 blocks the effects of GLT-1 upregulation on prepulse inhibition of the startle reflex in adult rats.	LY 379268	21-29	solute carrier family 1 member 2	Rattus norvegicus	52-57
20072121-3	2010	In this study, we tested the hypothesis that administration of the mGluR2/3 agonist LY379268 blocks the effect of GLT-1 upregulation on PPI of the startle.	LY 379268	84-92	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	67-73
20072121-3	2010	In this study, we tested the hypothesis that administration of the mGluR2/3 agonist LY379268 blocks the effect of GLT-1 upregulation on PPI of the startle.	LY 379268	84-92	solute carrier family 1 member 2	Rattus norvegicus	114-119
20072121-4	2010	We showed that administration of LY379268 (1 mg/kg) prevented PPI alterations associated with GLT-1 upregulation, suggesting that CEF-induced PPI impairment was mGluR2/3 dependent.	LY 379268	33-41	solute carrier family 1 member 2	Rattus norvegicus	94-99
20072121-4	2010	We showed that administration of LY379268 (1 mg/kg) prevented PPI alterations associated with GLT-1 upregulation, suggesting that CEF-induced PPI impairment was mGluR2/3 dependent.	LY 379268	33-41	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	161-167
20091783-3	2010	Activation of mGlu3 receptors with LY379268 (100 nM, applied every other day), during the differentiation period, impaired astrocyte differentiation, favoring the maintenance in culture of proliferating progenitors co-expressing GFAP with the immature markers, Sox1 and nestin.	LY 379268	35-43	glial fibrillary acidic protein	Mus musculus	229-233
20091783-3	2010	Activation of mGlu3 receptors with LY379268 (100 nM, applied every other day), during the differentiation period, impaired astrocyte differentiation, favoring the maintenance in culture of proliferating progenitors co-expressing GFAP with the immature markers, Sox1 and nestin.	LY 379268	35-43	SRY (sex determining region Y)-box 1	Mus musculus	261-265
20085613-5	2010	A mGluR3 selective agonist, LY379268, reduced inducible NO synthase expression and NO release induced by bacterial lipopolysaccharide and interferon-gamma in cultured rat astrocytes.	LY 379268	28-36	glutamate receptor, ionotropic, AMPA3 (alpha 3)	Mus musculus	2-8
19909793-0	2010	Group II metabotropic glutamate receptor activation by agonist LY379268 treatment increases the expression of brain derived neurotrophic factor in the mouse brain.	LY 379268	63-71	brain derived neurotrophic factor	Mus musculus	110-143
19909793-3	2010	By using in situ hybridization and western blotting methods the aim of present study was to analyse the potential regulatory role of selective mGluR2/3 agonist LY379268 treatment on brain derived neurotrophic factor (BDNF) expression in the mouse brain.	LY 379268	160-168	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	143-149
19909793-3	2010	By using in situ hybridization and western blotting methods the aim of present study was to analyse the potential regulatory role of selective mGluR2/3 agonist LY379268 treatment on brain derived neurotrophic factor (BDNF) expression in the mouse brain.	LY 379268	160-168	brain derived neurotrophic factor	Mus musculus	182-215
19909793-3	2010	By using in situ hybridization and western blotting methods the aim of present study was to analyse the potential regulatory role of selective mGluR2/3 agonist LY379268 treatment on brain derived neurotrophic factor (BDNF) expression in the mouse brain.	LY 379268	160-168	brain derived neurotrophic factor	Mus musculus	217-221
19909793-4	2010	The treatment with LY379268 evidenced a significant upregulation of BDNF mRNA levels in the cerebral cortex and in the hippocampal formation with a peak at 3 h from treatment and its disappearance already at 6 h from treatment.	LY 379268	19-27	brain derived neurotrophic factor	Mus musculus	68-72
19909793-5	2010	An analysis of dose-effect curve revealed that LY379268 may significantly enhance BDNF mRNA expression already at dose of 0.250 mg/kg b.w.	LY 379268	47-55	brain derived neurotrophic factor	Mus musculus	82-86
19909793-6	2010	The upregulation of BDNF mRNA expression was followed by a significant increase of BDNF protein levels at 24 h from LY379268 treatment.	LY 379268	116-124	brain derived neurotrophic factor	Mus musculus	20-24
19909793-6	2010	The upregulation of BDNF mRNA expression was followed by a significant increase of BDNF protein levels at 24 h from LY379268 treatment.	LY 379268	116-124	brain derived neurotrophic factor	Mus musculus	83-87
19909793-7	2010	These effects of LY379268 treatment on BDNF expression were restricted to neuronal cells and were blocked by the new selective mGlu2/3 receptor antagonist LY341495, suggesting a receptor specificity.	LY 379268	17-25	brain derived neurotrophic factor	Mus musculus	39-43
20085613-5	2010	A mGluR3 selective agonist, LY379268, reduced inducible NO synthase expression and NO release induced by bacterial lipopolysaccharide and interferon-gamma in cultured rat astrocytes.	LY 379268	28-36	interferon gamma	Rattus norvegicus	138-154
20085613-7	2010	LY379268 prevented astrocyte death induced by NO exposure, which correlates with a reduction in: phosphatidylserine externalization, p53 and Bax activation and mitochondrial permeability.	LY 379268	0-8	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	133-136
20085613-7	2010	LY379268 prevented astrocyte death induced by NO exposure, which correlates with a reduction in: phosphatidylserine externalization, p53 and Bax activation and mitochondrial permeability.	LY 379268	0-8	BCL2 associated X, apoptosis regulator	Rattus norvegicus	141-144
20085613-8	2010	The reported effects of LY379268 were prevented by the mGluR3 antagonist (s)-alpha-ethylglutamic acid.	LY 379268	24-32	glutamate receptor, ionotropic, AMPA3 (alpha 3)	Mus musculus	55-61
19672295-6	2009	GDNF mRNA levels peaked at 3 h and declined afterwards, whereas GDNF protein levels progressively increased from 24 to 72 h following LY379268 injection.	LY 379268	134-142	glial cell line derived neurotrophic factor	Mus musculus	64-68
19703487-2	2009	The purpose of the current study was to determine the effects of the mGluR2/3 agonist, LY379268, on cocaine-induced changes in DA neurochemistry in nonhuman primates.	LY 379268	87-95	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	69-75
19672295-9	2009	In pure cultures of striatal neurons, the increase in GDNF induced by LY379268 required the activation of the mitogen-activated protein kinase and phosphatidylinositol-3-kinase pathways, as shown by the use of specific inhibitors of the two pathways.	LY 379268	70-78	glial cell line derived neurotrophic factor	Mus musculus	54-58
19672295-11	2009	Remarkably, acute or repeated injections of LY379268 at doses that enhanced striatal GDNF levels (0.25 or 3 mg/kg, i.p.)	LY 379268	44-52	glial cell line derived neurotrophic factor	Mus musculus	85-89
19071114-6	2009	However, both in PINK1(-/-) and Parkin(-/-) mice, LY379268, but not L-AP4, exhibited a greater potency as compared to WT in depressing EPSP amplitude.	LY 379268	50-58	PTEN induced putative kinase 1	Mus musculus	17-22
19439499-8	2009	Systemic LY379268 inhibited DOI-stimulated PI hydrolysis in mice lacking either mGlu2 or mGlu3 receptors but was inactive in double mGlu2/mGlu3 receptor knockout mice, suggesting that both mGlu2 and mGlu3 receptors interact with 5-HT(2A) receptors.	LY 379268	9-17	glutamate receptor, metabotropic 3	Mus musculus	89-94
19439499-8	2009	Systemic LY379268 inhibited DOI-stimulated PI hydrolysis in mice lacking either mGlu2 or mGlu3 receptors but was inactive in double mGlu2/mGlu3 receptor knockout mice, suggesting that both mGlu2 and mGlu3 receptors interact with 5-HT(2A) receptors.	LY 379268	9-17	glutamate receptor, metabotropic 3	Mus musculus	138-143
19439499-8	2009	Systemic LY379268 inhibited DOI-stimulated PI hydrolysis in mice lacking either mGlu2 or mGlu3 receptors but was inactive in double mGlu2/mGlu3 receptor knockout mice, suggesting that both mGlu2 and mGlu3 receptors interact with 5-HT(2A) receptors.	LY 379268	9-17	glutamate receptor, metabotropic 3	Mus musculus	138-143
19071114-8	2009	Moreover, consistent with a presynaptic site of action, both LY379268 and L-AP4 increased the paired-pulse ratio either in PINK1(-/-) and Parkin(-/-) or in WT mice.	LY 379268	61-69	PTEN induced putative kinase 1	Mus musculus	123-128
18590921-4	2008	Accordingly, the selective mGlu2/3 receptor agonist, LY379268 (1microM) reduced forskolin-stimulated cAMP formation by 56% and 32% in hippocampal slices from FRL and FSL rats, respectively.	LY 379268	53-61	glutamate receptor, metabotropic 3	Mus musculus	27-34
18550032-6	2008	Treatment with haloperidol or LY379268 normalized novelty-induced locomotor hyperactivity in GLAST KO.	LY 379268	30-38	solute carrier family 1 (glial high affinity glutamate transporter), member 3	Mus musculus	93-98
19128205-8	2008	The mGluR2/3 agonist LY379268 is effective in inhibiting cocaine seeking in preclinical animal models and could decrease stress-induced relapse due to its anxiolytic effects.	LY 379268	21-29	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	4-10
17895914-0	2008	Rats with extended access to cocaine exhibit increased stress reactivity and sensitivity to the anxiolytic-like effects of the mGluR 2/3 agonist LY379268 during abstinence.	LY 379268	145-153	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	127-134
18442882-2	2008	We demonstrated that acute and chronic administration of MPEP (mGluR5 antagonist), LY379268 (mGluR2/3 agonist), and AMN082 (mGluR7 agonist) attenuated allodynia (von Frey test) and hyperalgesia (cold plate test) as measured in Swiss albino mice on day seven after chronic constriction injury (CCI) to the sciatic nerve.	LY 379268	83-91	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	93-99
18242587-7	2008	Local infusion of a non-selective mGlu2/3 agonist, LY379268, in the reticular nucleus of the thalamus, significantly reduced GABA release, suggesting that mGlu3 may also play a role in central disinhibition.	LY 379268	51-59	glutamate receptor, metabotropic 3	Mus musculus	155-160
18420113-5	2008	Therefore, the present study was designed to determine the effects the mGluR2/3 agonist LY379268 and the mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) on ethanol withdrawal-induced seizure activity.	LY 379268	88-96	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	71-77
16893525-0	2007	Systemic and central amygdala injections of the mGluR(2/3) agonist LY379268 attenuate the expression of incubation of cocaine craving.	LY 379268	67-75	glutamate receptor, metabotropic 2	Mus musculus	48-57
18057917-0	2008	The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity.	LY 379268	83-91	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	65-71
18057917-4	2008	OBJECTIVES: The aim of this study is to use recently generated mGluR3 and mGluR2 knockout mice to investigate which of the group II mGluRs mediates the actions of the mGluR2/3 agonist, LY379268, in two mouse models predictive of antipsychotic activity.	LY 379268	185-193	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	167-173
18057917-8	2008	One milligram per kilogram of LY379268 reversed PCP-evoked hyperactivity and behavioural alterations in wild-type (WT) and mGluR3 knockout mice but not in mice lacking mGluR2.	LY 379268	30-38	glutamate receptor, ionotropic, AMPA3 (alpha 3)	Mus musculus	123-129
18057917-9	2008	Similarly, 3 mg/kg LY379268 reversed amphetamine-evoked hyperactivity in WT and mGluR3 knockout mice but not in mice lacking mGluR2.	LY 379268	19-27	glutamate receptor, ionotropic, AMPA3 (alpha 3)	Mus musculus	80-86
18057917-10	2008	CONCLUSION: The mGlu2 but not the mGlu3 receptor subtype mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity.	LY 379268	103-111	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	85-91
17537525-0	2007	Systemic and central amygdala injections of the mGluR2/3 agonist LY379268 attenuate the expression of incubation of sucrose craving in rats.	LY 379268	65-73	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	48-54
17537525-1	2007	We previously reported that systemic or central amygdala injections of the mGluR(2/3) agonist LY379268 (which decreases glutamate release) prevented enhanced cue-induced cocaine seeking in extinction tests after prolonged withdrawal (incubation of cocaine craving).	LY 379268	94-102	glutamate receptor, metabotropic 2	Mus musculus	75-84
17293559-2	2007	We show that pharmacological activation of A(1) adenosine and mGlu3 metabotropic glutamate receptors with N(6)-chlorocyclopentyladenosine (CCPA) and (-)2-oxa-4-aminocyclo-[3.1.0]hexane-4,6-dicarboxylic acid (LY379268), respectively, protects cultured astrocytes against apoptosis induced by a 3-h exposure to oxygen/glucose deprivation (OGD).	LY 379268	208-216	glutamate receptor, metabotropic 3	Mus musculus	62-67
17293559-4	2007	Both in control astrocytes and in astrocytes exposed to OGD, CCPA and LY379268 induced a rapid activation of the phosphatidylinositol-3-kinase (PI3K) and extracellular signal-regulated kinases 1 and 2 (ERK1/2)/mitogen-activated protein kinase (MAPK) pathways, which are known to support cell survival.	LY 379268	70-78	mitogen-activated protein kinase 1	Homo sapiens	154-200
17293559-4	2007	Both in control astrocytes and in astrocytes exposed to OGD, CCPA and LY379268 induced a rapid activation of the phosphatidylinositol-3-kinase (PI3K) and extracellular signal-regulated kinases 1 and 2 (ERK1/2)/mitogen-activated protein kinase (MAPK) pathways, which are known to support cell survival.	LY 379268	70-78	mitogen-activated protein kinase 3	Homo sapiens	202-208
17293559-5	2007	In cultures exposed to OGD, CCPA and LY379268 reduced the activation of c-Jun N-terminal kinase and p38/MAPK, reduced the levels of the proapoptotic protein Bad, increased the levels of the antiapoptotic protein Bcl-X(L), and were highly protective against apoptotic death, as shown by nuclear 4"-6-diamidino-2-phenylindole staining and measurements of caspase-3 activity.	LY 379268	37-45	mitogen-activated protein kinase 1	Homo sapiens	100-103
17293559-5	2007	In cultures exposed to OGD, CCPA and LY379268 reduced the activation of c-Jun N-terminal kinase and p38/MAPK, reduced the levels of the proapoptotic protein Bad, increased the levels of the antiapoptotic protein Bcl-X(L), and were highly protective against apoptotic death, as shown by nuclear 4"-6-diamidino-2-phenylindole staining and measurements of caspase-3 activity.	LY 379268	37-45	BCL2 like 1	Homo sapiens	212-220
17293559-5	2007	In cultures exposed to OGD, CCPA and LY379268 reduced the activation of c-Jun N-terminal kinase and p38/MAPK, reduced the levels of the proapoptotic protein Bad, increased the levels of the antiapoptotic protein Bcl-X(L), and were highly protective against apoptotic death, as shown by nuclear 4"-6-diamidino-2-phenylindole staining and measurements of caspase-3 activity.	LY 379268	37-45	caspase 3	Homo sapiens	353-362
16893525-3	2007	Here, we further explored the role of central amygdala glutamate in the incubation of cocaine craving by determining the effect of systemic or central amygdala injections of the mGluR2/3 agonist LY379268 (which decreases glutamate release) on cue-induced cocaine seeking during early and late withdrawal.	LY 379268	195-203	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	178-184
16341024-2	2006	In an initial pharmacological characterization, we found that the mGluR2/3 agonist LY379268, which acts centrally to reduce evoked glutamate release, attenuates context-induced reinstatement of heroin seeking when injected systemically or into the ventral tegmental area, the cell body region of the mesolimbic dopamine system.	LY 379268	83-91	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	66-72
16834996-0	2006	The mGluR2/3 agonist LY379268 attenuates context- and discrete cue-induced reinstatement of sucrose seeking but not sucrose self-administration in rats.	LY 379268	21-29	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	4-10
16834996-1	2006	We recently reported that systemic injections of the mGluR(2/3) agonist LY379268, which decreases evoked glutamate release, attenuate context- and discrete cue-induced reinstatement of heroin seeking, but not heroin self-administration.	LY 379268	72-80	glutamate receptor, metabotropic 2	Mus musculus	53-62
17196590-6	2007	Pharmacological activation of mGlu2/3 receptors by systemic injection of LY379268 (0.5 mg/kg, i.p., 15 min before the onset of anoxia) substantially protected retinas against anoxia-induced cell death.	LY 379268	73-81	glutamate receptor, metabotropic 3	Mus musculus	30-37
16503796-5	2006	The neuroprotective effect of LY379268 in vitro was abolished by co-administration of the mGluR2/3 antagonist (s)-alpha-ethylglutamic acid (EGLU); however, co-application of selective mGluR3 antagonist beta-N-acetyl-aspartyl-glutamate (NAAG) had no significant influence in the same system.	LY 379268	30-38	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	90-96
16503796-5	2006	The neuroprotective effect of LY379268 in vitro was abolished by co-administration of the mGluR2/3 antagonist (s)-alpha-ethylglutamic acid (EGLU); however, co-application of selective mGluR3 antagonist beta-N-acetyl-aspartyl-glutamate (NAAG) had no significant influence in the same system.	LY 379268	30-38	glutamate receptor, ionotropic, AMPA3 (alpha 3)	Mus musculus	184-190
15857619-14	2005	In addition they reveal a "stress-like" increase in NE after high doses of LY379268 which may reflect mGlu3 receptor modulation of GABAergic transmission.	LY 379268	75-83	glutamate receptor, metabotropic 3	Mus musculus	102-107
16123306-4	2005	LY487379 and LY379268 [(-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate], an ortho-steric mGlu2/3 receptor agonist, induced similar dose-dependent reductions in PCP- and amphetamine-induced hyperlocomotor activity in C57BL6/J mice at doses that did not significantly alter spontaneous locomotor activity.	LY 379268	13-21	glutamate receptor, metabotropic 3	Mus musculus	97-104
15931079-0	2005	The novel mGluR2/3 agonist LY379268 attenuates cue-induced reinstatement of heroin seeking.	LY 379268	27-35	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	10-16
15931079-4	2005	Here, we determined the effect of LY379268, an mGluR2/3 agonist that decreases evoked glutamate release, on cue-induced reinstatement of heroin seeking.	LY 379268	34-42	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	47-53
12429591-4	2002	Selective agonists of mGlu2 and -3 receptor subtypes [compounds LY379268 and (2S,2"R,3"R)-2-(2",3"-[(3)H]-dicarboxycyclopropyl)glycine ([(3)H]DCG-IV)] exhibited a much greater potency in depressing excitatory transmission and corticostriatal synapses in slices prepared from 6-OHDA-lesioned animals.	LY 379268	64-72	glutamate receptor, metabotropic 3	Mus musculus	22-34
15306259-0	2004	The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington"s disease.	LY 379268	77-85	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	62-68
12842121-10	2003	We conclude that mGlu2/3 receptors play a protective role against MPTP toxicity, and that the efficacy of the agonist, LY379268, critically depends on the extent of the nigro-striatal lesion.	LY 379268	119-127	glutamate receptor, metabotropic 3	Mus musculus	17-24
12496939-6	2003	Pretreatment with the mGlu2/3 agonist LY379268 attenuated the DOI-induced increase in the prefrontal cortex.	LY 379268	38-46	glutamate receptor, metabotropic 3	Mus musculus	22-29
14598016-10	2004	In tests of antagonism, stimulus control by LSD was significantly but incompletely diminished by the mGlu(2/3) agonist, LY379268; this result was in contrast with the complete antagonism of LSD by both pirenperone and M100907.	LY 379268	120-128	glutamate receptor, metabotropic 3	Mus musculus	101-109
14529950-9	2003	The largest protective indices (P.I.=TD50/ED50) observed were associated with the iGlu5 antagonist LY382884 and the mGlu2/3 receptor agonists LY379268 and LY389795 (P.I.=>14, 14, and 4.9, respectively) in the 6 Hz model.	LY 379268	142-150	glutamate receptor, metabotropic 3	Mus musculus	116-123
12784113-0	2003	Toluene-induced locomotor activity is blocked by 6-hydroxydopamine lesions of the nucleus accumbens and the mGluR2/3 agonist LY379268.	LY 379268	125-133	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	108-114
11483646-5	2001	Activation of the MAPK and PI-3-K pathways in cultured astrocytes treated with 4C3HPG or LY379268 was directly demonstrated by an increase in the phosphorylated forms of ERK-1/2 and Akt.	LY 379268	89-97	mitogen activated protein kinase 3	Rattus norvegicus	18-22
11483646-5	2001	Activation of the MAPK and PI-3-K pathways in cultured astrocytes treated with 4C3HPG or LY379268 was directly demonstrated by an increase in the phosphorylated forms of ERK-1/2 and Akt.	LY 379268	89-97	mitogen activated protein kinase 3	Rattus norvegicus	170-177
11483646-5	2001	Activation of the MAPK and PI-3-K pathways in cultured astrocytes treated with 4C3HPG or LY379268 was directly demonstrated by an increase in the phosphorylated forms of ERK-1/2 and Akt.	LY 379268	89-97	AKT serine/threonine kinase 1	Rattus norvegicus	182-185
11445181-5	2001	Both mGlu(2/3) agonists inhibited seizures induced by the group I mGlu receptor agonist (R,S)-3,5-dihydroxyphenylglycine (DHPG), where LY379268, i.c.v.	LY 379268	135-143	glutamate receptor, metabotropic 3	Mus musculus	5-13
11378155-1	2001	Our recent work (Cartmell et al., Journal of Neurochemistry, 75 (2000) 1147-1154) demonstrated that systemic injection of the potent, selective mGlu2/3 receptor agonist, LY379268, acutely increased extracellular levels of dopamine, its metabolites DOPAC and HVA, and the 5-HT metabolite, 5-HIAA, in rat medial prefrontal cortex (mPFC).	LY 379268	170-178	complement factor properdin	Mus musculus	329-333
11378155-2	2001	Here, we compared the acute effects of LY379268 with those of clozapine and risperidone (atypical antipsychotics) on extracellular levels of both dopamine and 5-HT in the mPFC of freely-moving rats.	LY 379268	39-47	complement factor properdin	Mus musculus	171-175
10945827-5	2000	Furthermore, 24- or 48-h pretreatment with LY379268, 10 mg/kg i.p., before 5-min BCAO markedly reduced (P <.001 and P <.05, respectively) the damage to CA1 hippocampal neurons.	LY 379268	43-51	carbonic anhydrase 1	Homo sapiens	158-161